The Dual/Global Value of SARS-CoV-2 Genome Surveillance on Migrants Arriving to Europe via the Mediterranean Routes

CLAUDIA MAROTTA
PAOLA STEFANELLI
FABIO TRAMUTO
ULRICO ANGELONI
CARMELO MASSIMO MAIDA
ACHILLE CERNIGLIARO
TERESA BARONE
FRANCESCO VITALE
GIOVANNI REZZA
WALTER MAZZUCCO
FOR THE SAMI-SURV COLLABORATION*

*Author affiliations can be found in the back matter of this article

ABSTRACT

Despite the pandemic, 34,154 migrants, refugees or asylum-seekers landed in Sicily (Italy) in 2020, representing the main point of entry by sea into Europe. The SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea, made by the combination of clinical examination and molecular testing, has been integrated by full-genome sequencing strains using the NGS technology from the last week of February. To date, more than one hundred full-genome strains have been sequenced and 8 different lineages have been identified mostly belonging to the lineages B.1.1.7 and B.1.525. As global access to COVID-19 vaccines should be ensured, the need to provide more detailed information to inform policies and to drive the possible re-engineering of vaccines needed to deal with the challenge of new and future variants should be highlighted.
Since the first cases of pneumonia were reported in Wuhan, genomic epidemiology is playing a major role in the characterization and comprehension of SARS-CoV-2 pandemic thanks to the sharing of viral sequences. In particular, the study of the genetic diversity and evolutionary dynamics of SARS-CoV-2 contributes to real-time surveillance and to the understanding of antigenic changes and virus transmission patterns [1]. Moreover, if on one side virus genome sequencing can improve control measures, diagnostic capacity, the detection of infection sources and patterns of infection, disease prognosis, and vaccine effectiveness [2]; it can also provide knowledge on the impact of SARS-CoV-2 variants resistant to neutralization by monoclonal and serum-derived polyclonal antibodies [3]. For all of the aforementioned reasons, in the context of a pandemic, where only global responses may be truly successful, robust amounts of molecular knowledge from SARS-CoV-2 viruses circulating around the world are needed, even in low-resource settings where low-to-absent testing capacity and poor reporting systems are in place [4].

In September 2020, a network of laboratories was launched in Africa by the WHO and the African Centres for Disease Control and Prevention to accelerate genomic-based surveillance for COVID-19 response in the continent [5–8]. Nevertheless, although the number of genome sequences available in the GISAID from Africa is rapidly increasing, an important information gap should be filled and much remains to be done to build a comprehensive and detailed picture [9].

At the same time, since its inception, the COVID-19 pandemic has shown the immense risks of lacking a global health perspective when coping with such health threats. Despite this, one year after the first COVID-19 documented cases, the lesson is yet to be learnt, with responses running at various speeds in both high and low-middle income countries, in terms of diagnostic and surveillance capacities, health workforce, therapeutic options, and, not least, vaccination campaigns.

In this changing scenario, introducing genomic surveillance in migrants arriving to Italy by the Mediterranean Sea via the Tunisian or Libyan routes may have dual/global value. On one hand, it reflects what happens in the place where their journey began or, more often, in the final leg of their very long journey, because for the majority of them Libya represents a last – very long – pause before Europe, bringing migrants from various countries and continents together [10]. On the other hand, through its islands facing the far south (Figure 1), Italy is the closest territory to African

---

**Figure 1** Countries of origin and routes followed by migrants to Europe through the points of entry in Southern Italy.
borders and – counting the 34,154 migrants, refugees or asylum-seekers who arrived in 2020 – represents the main point of entry by sea into Europe [11]. Thus, analysing in depth what happens at this level may improve our understanding of the global SARS-CoV-2 transmission dynamic, particularly in light of the emergence of new variants, while at the same time representing an opportunity to forecast future epidemiological scenarios [12].

To this end, we have scaled up the SARS-CoV-2 surveillance program among migrants arriving to Sicily via the Mediterranean Sea through the Libyan and Tunisian routes, rescued by non-governmental organizations and/or military navy patrolling the area or landed on their own, integrating it with genomics and establishing the SARS-CoV-2 Migrants Surveillance (SAMI-Surv) Collaboration for scientific purposes.

More in depth, since the beginning of pandemic, each single migrant arriving in Italy – already undergoing a medical screening according to the International Health Regulation provisions – has been tested for SARS-CoV-2 with a rapid antigen test at the moment of arrival. If the subject tests positive, a RT-PCR is performed and, if confirmed, the subject is isolated. Regardless of the rapid antigen results, because migrants are all coming from a “high risk area for SARS-CoV-2” according to Italian law, they are all quarantined for 10 days with a second test performed at the end of the period if no symptoms occur before this.

Both isolated and quarantined migrants are hosted in dedicated reception camps or, more often, in reconverted cruise ships organized in areas an by cohorts.

Starting from the last week of February 2021, the already ongoing surveillance upon migrants’ arrivals, carried out through the combination of clinical examination and molecular testing as described above, has been integrated with full-genome sequencing strains using the next generation sequencing (NGS) technology. To date, more than one hundred full-genome SARS-CoV-2 sequences have been obtained out of 2,536 positive migrant subjects monitored through the surveillance system in place. Most of them were young males (83.7%, median age 22.5 years old) who followed the Mediterranean Sea routes from low-resource countries (Egypt: 18.5%; Bangladesh: 13.1%; Somalia: 9.8%; Morocco: 7.6%; Tunisia: 6.5%, etc.). Eight different lineages have been identified, mostly belonging to the lineages B.1.525 (59.0%) and B.1.1.7 (31.0%), followed by C.36 (4.0%) and A.27 (2.0%) (Figure 1). Interestingly, although the aforementioned lineages have been relatively uncommon in this area of the globe [9], a number of “variants of concern” are beginning to gain more relevance during the most recent period [13]. This body of evidence highlights, on one side, how the phylogenetic classification system is very dynamic in relation to the natural evolutionary and adaptive processes, favouring the emergence of new viral lineages with higher fitness, and, on the other side, the role that genomic surveillance program on migrants arriving from under-sampled regions across the globe can play at their destination countries.

As the SAMI-Surv collaboration also aims to provide further evidence in support of global access to COVID-19 vaccines [14], more detailed information from our experience will be shared soon with the hope of providing early strategic information to national and global scientific communities to inform policies and, potentially, to drive the re-engineering of vaccines needed to deal with the challenge of new and future variants [15].

**FUNDING INFORMATION**

Project funded by the Ministry of Health – Centers for Prevention and Disease Control “Sorveglianza epidemiologica e controllo del COVID-19 in aree urbane metropolitane e per il contenimento della circolazione del SARS-CoV-2 nella popolazione immigrata in Italia” (B74G20000070001).

**COMPETING INTERESTS**

The authors have no competing interests to declare.
AUTHOR CONTRIBUTIONS
CM wrote the first draft of manuscript; FT created the figure and carried out the genomic analyses; WM supervised the editing of the manuscript. All listed authors had full data access, reviewed the manuscript and approved the final, submitted version.

AUTHOR AFFILIATIONS
Claudia Marotta, MD  
General Directorate of Health Prevention, Ministry of Health, Rome, Italy
Paola Stefanelli, MSc  
Department of Infectious Diseases, National Institute of Health (ISS), Italy
Fabio Tramuto, MSc  
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy; Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital “P. Giaccone”, Palermo, Italy
Ulrico Angeloni, MD  
General Directorate of Health Prevention, Ministry of Health, Rome, Italy
Carmelo Maida, MSc  
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy; Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital “P. Giaccone”, Palermo, Italy
Achille Cernigliaro, MSc  
Regional Health Authority of Sicily, Palermo, Italy
Teresa Barone, MD  
Department of Laboratory Diagnostics, Local Health Unit of Palermo, Palermo, Italy
Francesco Vitale, Prof  
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy; Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital “P. Giaccone”, Palermo, Italy
Giovanni Rezza, Prof  
General Directorate of Health Prevention, Ministry of Health, Rome, Italy
Walter Mazzucco, Prof  
Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties “G. D’Alessandro”, University of Palermo, Italy; Clinical Epidemiology Unit and Regional Reference Laboratory of Western Sicily for the Emergence of COVID-19, University Hospital “P. Giaccone”, Palermo, Italy; Division of Biostatistics & Epidemiology Research, Cincinnati Children’s Hospital Medical Center, United States

The SAMI-Surv Collaboration
Davide Alba, Emanuele Arnadía, Alessandra Casuccio, Claudio Costantino, Santo Fruscione, Vincenzo Restivo, Alessandra Savatteri (University of Palermo); Nadia D’Agostino, Daniele La Milia, Laura Pecoraro, Claudio Pulvirenti, Domenico Stabile (USMAF Sicilian Unit); Carlo Cesari, Salvatore Zichichi (Italian Red Cross); Alessandra Lo Presti (Italian National Health Institute); Daniela Di Naro, Giorgio Graziano, Giulia Randazzo (COVID-19 western Sicily reference lab); Salvatore Scondotto (Regional Health Authority of Sicily); Stefano Reale, Silvia Scibetta, Fabrizio Vitale (Experimental Zoo-prophylactic Institute of Sicily); Rosario Asciutto, Ranieri Candura, Mariana Lucchese, Giulio Mangano, Maristella Messina, Giuseppe Mistretta, Giulia Palmeri, Antonina Patrizia Rizzo, Antonino Sparaco (Local Health Unit of Trapani); Annalisa Agnone, Francesco Cascio, Daniela Laura Di Quarto, Carmelo Migliorisi (Local Health Unit of Palermo); Stefania D’Amato (Italian Ministry of Health); Vittorio Spoto, Mario Zappia (Local Health Unit of Agrigento).

REFERENCES
1. Islam MR, Hoque MN, Rahman MS, et al. Genome-wide analysis of SARS-CoV-2 virus strains circulating worldwide implicates heterogeneity. Sci Rep. 2020; 10(1): 14004. DOI: https://doi.org/10.1038/s41598-020-70812-6
2. Young BE, Fong S-W, Chan Y-H, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: An observational cohort study. Lancet. 2020; 396(10251): 603–11. DOI: https://doi.org/10.1016/S0140-6736(20)31757-8
3. Chen RE, Zhang X, Case JB, et al. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nat Med. 2021. DOI: https://doi.org/10.1038/s41591-021-01294-w
4. COVID-19 WHO African Region. External situation report 31. Who.int. Available from: https://apps.who.int/iris/bitstream/handle/10665/335766/SITREP_COVID-19_WHOAFRO_20200930-eng.pdf?ua=1 [Accessed 21 Mar 2021].

5. Motayo BO, Oluwasemowo OO, Oluosingo BA, et al. Evolution and genetic diversity of SARS-CoV-2 in Africa using whole genome sequences. Int J Infect Dis. 2021; 103: 282–7. DOI: https://doi.org/10.1016/j.ijid.2020.11.190

6. World Health Organization. COVID-19 genome sequencing laboratory network launches in Africa, 2020. Available from: https://www.afro.who.int/news/covid-19-genome-sequencing-laboratory-network-launches-africa [Accessed 21 Mar 2021].

7. Tessema SK, Inzaule SC, Christoffels A, et al. Accelerating genomics-based surveillance for COVID-19 response in Africa. Lancet Microbe. 2020; 1(6): e227–8. DOI: https://doi.org/10.1016/S2666-5247(20)30117-8

8. Inzaule SC, Tessema SK, Kebede Y, Ogwell Ouma AE, Nkengasong JN. Genomic-informed pathogen surveillance in Africa: Opportunities and challenges. Lancet Infect Dis. 2021. DOI: https://doi.org/10.1016/S1473-3099(20)30939-7

9. Lu L, Lycett S, Ashworth J, Mutapi F, Woolhouse M. What are SARS-CoV-2 genomes from the WHO Africa region member states telling us? BMJ Glob Health. 2021; 6(1): e004408. DOI: https://doi.org/10.1136/bmjgh-2020-004408

10. Daw M, El-Bouzedi A, Ahmed M. COVID-19 and African immigrants in North Africa: A hidden pandemic in a vulnerable setting. Disaster Medicine and Public Health Preparedness. 2020; 1–2. DOI: https://doi.org/10.1017/dmp.2020.387

11. Italian Republic Ministry of Internal Affairs. Department of civilian freedom and migration. Available from: http://www.libertaciviliimmigrazione.dlci.interno.gov.it/sites/default/files/allegati/cruscotto_statistico_giornaliero_31-12-2020_1.pdf [Accessed 21 Mar 2021].

12. Tramuto F, Reale S, Lo Presti A, et al. Genomic analysis and lineage identification of SARS-CoV-2 strains isolated from migrants travelling through the Libyan route. Frontiers in Public Health. 2021; 9: 181. DOI: https://doi.org/10.3389/fpubh.2021.632645

13. Ozer EA, Simons LM, Adewumi OM, et al. High prevalence of SARS-CoV-2 B.1.1.7 (UK variant) and the novel B.1.525 lineage in Oyo State, Nigeria. medRxiv. 2021; 04(09): 21255206. DOI: https://doi.org/10.1101/2021.04.09.21255206

14. Wouters OJ, Shadlen KC, Salcher-Konrad M, et al. Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. Lancet. 2021 Mar 13; 397(10278): 1023–1034. DOI: https://doi.org/10.1016/S0140-6736(21)00306-8

15. Kupferschmidt K. New mutations raise specter of ‘immune escape’. Science. 2021; 6527: 329–30. DOI: https://doi.org/10.1126/science.371.6527.329